Achieve comprehensive blood sugar stability with Galvus Met 50/850mg, a high-performance combination therapy for Type 2 Diabetes Mellitus. By uniting two potent antidiabetic agents—Vildagliptin and Metformin Hydrochloride—this medication addresses the complex nature of glucose regulation from multiple angles. Vildagliptin enhances the body's natural incretin system to boost insulin secretion when needed, while Metformin improves insulin sensitivity and reduces the liver's glucose production. Galvus Met is specifically indicated for patients who require stronger glycemic control than single-drug therapy can provide. Its balanced formula helps lower HbA1c levels effectively with a low risk of hypoglycemia and a weight-neutral profile, making it a cornerstone for long-term health and the prevention of diabetes-related complications.

• Dual-Mechanism Synergy: Combines DPP-4 inhibition with improved insulin sensitivity.

• Superior HbA1c Reduction: More effective than either Vildagliptin or Metformin used alone.

• Hepatic Glucose Control: Metformin targets fasting glucose by reducing liver sugar output.

• Physiological Insulin Boost: Vildagliptin ensures insulin is released in response to meals.

• Patient Convenience: Two essential medications in a single, easy-to-manage tablet.

Usage Instructions:

• Dosage: Typically one tablet twice daily (morning and evening), or as prescribed by your physician.

• Administration: Must be taken with or after meals to minimize Metformin-related gastrointestinal side effects.